Hepatocellular Carcinoma

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

BOSTON — Transarterial chemoembolization with vitamin K dosing improved anticancer outcomes of objective response and progression-free survival in patients with hepatocellular carcinoma, according to a researcher at The Liver Meeting.

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

Durvalumab combined with transarterial chemoembolization and bevacizumab lengthened PFS among certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.

BOSTON — Metabolic dysfunction-associated steatohepatitis is currently the most common indication for liver transplantation in patients with hepatocellular carcinoma, increasing from 10% in 2013 to 31% in 2022, according to a presenter.

Liver Cancer Awareness Month, celebrated every October, seeks to raise awareness about the third deadliest cancer in the United States, with approximately 41,000 new cases and as many as 30,000 deaths each year.

Postdiagnosis antidepressant use reduced mortality risk among patients with hepatocellular carcinoma, according to data published in JAMA Network Open.

Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.

Failure to achieve sustained virological response and the presence of more advanced chronic liver disease were associated with mortality in patients with hepatitis C and hepatocellular carcinoma, according to a researcher at EASL Congress.